Perceive Biotherapeutics develops therapeutics targeting retinal degeneration by utilizing deep genetic insights to translate protective biology into clinical applications. The company focuses on preventing irreversible blindness caused by conditions such as dry age-related macular degeneration through a diversified pipeline of novel therapies.
Funding
$78M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related macular degeneration (AMD) and other retinal diseases lead to irreversible blindness, impacting a significant portion of the aging population. Current treatments are limited, and there is a need for novel therapies that can effectively prevent or slow down retinal degeneration.
Solution
Perceive Biotherapeutics is developing a pipeline of therapeutics focused on preventing retinal degeneration and protecting sight. The company leverages deep genetic insights and decades of academic research to identify and translate protective biology into clinical applications. Their approach centers on novel protective biologies and differentiated targets, utilizing multiple therapeutic modalities to address the underlying causes of irreversible blindness, with lead programs focused on dry AMD and neuroprotection.
Target Audience
The primary target audience includes patients at risk of or affected by retinal degeneration, including dry AMD, and the ophthalmologists and retinal specialists who treat them.
Features
- Diversified pipeline of assets targeting novel protective biologies in retinal degeneration.
- Therapeutic modalities designed to address the largest causes of irreversible blindness.
- Programs in development for dry AMD and neuroprotection.
- Exclusive access to decades of academic research elucidating protective biologies.